2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 7, 2017

9:00AM-11:00AM: Abstract Number: 2621

Minimal Renal Affection in Patients with Systemic LUPUS Erythematosus: Characteristics and Evolution

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design

9:00AM-11:00AM: Abstract Number: 2436

MiR-146a Upregulates the TLR4/NF-κb Signaling Pathway to Promote Cytokine Expression and Synovial Fibroblast Proliferation in Rheumatoid Arthritis

Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster III

9:00AM-11:00AM: Abstract Number: 1933

Mitochondrial ROS Activate the p38-MAPK/AP1 Pathway to Induce the Expression of Matrix Metalloproteases and IL-6 in Human Chondrocytes

Biology and Pathology of Bone and Joint Poster II

9:00AM-11:00AM: Abstract Number: 2124

Mixed Connective Tissue Disorder Has Higher Prevalence of Arthritis and Use of Methotrexate Than Systemic Lupus Erythematosus

Miscellaneous Rheumatic and Inflammatory Diseases Poster II

9:00AM-11:00AM: Abstract Number: 2326

Modeling Transcriptional Rewiring in Neutrophils through the Course of Treated Juvenile Idiopathic Arthritis

Pediatric Rheumatology – Pathogenesis and Genetics Poster

9:00AM-11:00AM: Abstract Number: 2314

Monoarticular Juvenile Idiopathic Arthritis: A Unique Entity?

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster III: Juvenile Arthritis

9:00AM-11:00AM: Abstract Number: 2329

Monocytes from Patients with Enthesitis Related Arthritis Produce High Levels of Pro-Inflammatory Cytokines: Role of Endogenous Ligands

Pediatric Rheumatology – Pathogenesis and Genetics Poster

9:00AM-11:00AM: Abstract Number: 2412

Mortality and Clinical Features in Rheumatoid Arthritis and Interstitial Lung Disease

Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2665

Mortality in an Early Diffuse Cutaneous Systemic Sclerosis Cohort—Data from the Prospective Registry for Early Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster III

9:00AM-11:00AM: Abstract Number: 2679

Mortality Is Increased in Scleroderma Associated Pulmonary Arterial Hypertension Patients with Younger Age, Lower Systolic Blood Pressure, and Lower Cardiac Index, but Not in Idiopathic Pulmonary Arterial Hypertension

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster III

9:00AM-11:00AM: Abstract Number: 2699

Mosaic, a Novel Gene, Mediating Autoimmunity in Mice

T Cell Biology and Targets in Autoimmune Disease Poster II

9:00AM-11:00AM: Abstract Number: 1988

Most Fibromyalgia Patients in a Rheumatology Office Practice Accept the Diagnosis of Fibromyalgia

ARHP Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes

9:00AM-11:00AM: Abstract Number: 2000

MRI Contributes to Accurate and Early Diagnosis of Non-Radiographic HLA-B27 Negative Axial Spondyloarthritis

Imaging of Rheumatic Diseases Poster II

9:00AM-11:00AM: Abstract Number: 2711

Mucosal-Associated Invariant T Cells Are an Important Source of TNF in Rheumatoid Arthritis

T Cell Biology and Targets in Autoimmune Disease Poster II

9:00AM-11:00AM: Abstract Number: 1959

Multimorbidity in Patients with Sarcoidosis: A Population-Based Cohort Study

Epidemiology and Public Health Poster III: Rheumatic Disease Risk and Outcomes

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].